Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Next Previous
X
Search
Trial Profile

Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icotinib (Primary) ; Cisplatin; Docetaxel; Pemetrexed
  • Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Betta Pharmaceuticals Co Ltd

    • Most Recent Events

    • 02 Jun 2017 Results (n=66) assessing efficacy of first line chemotherapy plus Icotinib maintenance presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Feb 2017 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
    • 07 Feb 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top